Discontinuation of Oral Anticoagulation After Successful Atrial Fibrillation Ablation - Are We Ready to Change Clinical Practice in 2026?

Atrial fibrillation (AF) is a complex cardiac arrhythmia that substantially compromises survival and quality of life. Patients with AF are predisposed to a substantially elevated risk of systemic embolism, including ischemic stroke. Clinical risk-stratification tools guide the initiation of oral anticoagulation (OAC) to mitigate these thromboembolic complications. However, chronic OAC is inherently associated with bleeding complications, some of which may be life-threatening. Historically, maintenance of OAC has remained the clinical standard even after successful catheter ablation and subsequent restoration of sinus rhythm. Given that the procedural efficacy of ablation has improved in recent years, the need for lifelong anticoagulation in patients without documented recurrences is increasingly questioned. Findings from recent randomized controlled trials - OCEAN and ALONE-AF - provide a new perspective on this clinical paradigm. Here, we integrated available data concerning this topic, with the goal of providing input into the ongoing debate. This review compares data from these landmark trials in the context of previous literature. Although current evidence supports discontinuation of OAC after successful catheter ablation, such data should be interpreted with caution due to the presence of high-risk cohorts and the persistent influence of the underlying atrial substrate. This review also analyzes clinical and imaging factors that identify high-risk patients who may be unsuitable for OAC discontinuation. We discuss the utility of left atrium functional assessment via speckle-tracking echocardiography. Furthermore, we examine strategies for high-fidelity rhythm surveillance and methods for managing subclinical recurrences. Finally, we summarize current evidence and propose directions for future research in personalized antithrombotic therapy.